Treatment of Severe Acute Respiratory Syndrome With Glucosteroids

Study objective To investigate the efficacy and safety profiles of corticosteroid therapy in severe acute respiratory syndrome (SARS) patients. Design Four hundred one of 1,278 SARS cases treated in Guangzhou China between December 2002 and June 2003 fulfilled the diagnostic criteria issued by the World Health Organization for confirmed identification of SARS. Among them, the diagnosis of critical SARS was defined by criteria of SARS guidelines incorporated with a low oxygenation index (OI) [< 300 mm Hg]. Data of these patients retrieved from a database were retrospectively analyzed by logistic regression and Cox regression for the effect of corticosteroid therapy on death, hospitalization days, and complication presentation. Results Among the 401 SARS patients studied, 147 of 249 noncritical patients (59.0%) received corticosteroids (mean daily dose, 105.3 ± 86.1 mg) [± SD], and all survived the disease; 121 of 152 critical patients (79.6%) received corticosteroids at a mean daily dose of 133.5 ± 102.3 mg, and 25 died. Analysis of these 401 confirmed cases did not show any benefits of corticosteroid on the death rate and hospitalization days. However, when focused on 152 critical SARS cases, factors correlated with these end points indicated by univariate analysis included use of corticosteroid, age, rigor at onset, secondary respiratory infections, pulmonary rales, grading of OI, and use of invasive ventilation. After adjustment for possible confounders, treatment with corticosteroid was shown contributing to lower overall mortality, instant mortality, and shorter hospitalization stay (p < 0.05). Incidence of complications was significantly associated with the need for invasive ventilation but not with use of corticosteroids. Conclusion This Guangzhou retrospective study revealed that proper use of corticosteroid in confirmed critical SARS resulted in lowered mortality and shorter hospitalization stay, and was not associated with significant secondary lower respiratory infection and other complications.

[1]  Jun Xu,et al.  Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome. , 2005, American journal of respiratory and critical care medicine.

[2]  A. Ahuja,et al.  Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. , 2005, Radiology.

[3]  M. Shinozaki.  [Respiratory and cadiovascular management of septic ALI-ARDS and shock]. , 2004, Nihon rinsho. Japanese journal of clinical medicine.

[4]  N. Zhong,et al.  [Report on the investigation of lower extremity osteonecrosis with magnetic resonance imaging in recovered severe acute respiratory syndrome in Guangzhou]. , 2004, Zhonghua yi xue za zhi.

[5]  V. Wong,et al.  Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients , 2004, Journal of Clinical Virology.

[6]  A. Wu,et al.  Medical treatment of viral pneumonia including SARS in immunocompetent adult , 2004, Journal of Infection.

[7]  J. Sung,et al.  Treatment of Severe Acute Respiratory Syndrome , 2004, Chest.

[8]  Li-Ming Chen,et al.  [Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence]. , 2004, Zhonghua yi xue za zhi.

[9]  N. Zhong.  Management and prevention of SARS in China. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[10]  N. Hong,et al.  Avascular necrosis of bone in severe acute respiratory syndrome , 2004, Clinical Radiology.

[11]  V. Wong,et al.  Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak , 2004, Thorax.

[12]  Wei-jun Chen,et al.  [Comparative study of clinical characteristics and prognosis of clinically diagnosed SARS patients with positive and negative serum SARS coronavirus-specific antibodies test]. , 2004, Zhonghua yi xue za zhi.

[13]  J. Sung,et al.  Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome , 2004, Clinical and experimental immunology.

[14]  Guang-wei Li,et al.  [Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy]. , 2004, Zhonghua nei ke za zhi.

[15]  J. Peiris,et al.  Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids , 2004, Clinical and experimental immunology.

[16]  W. M. Lee,et al.  High dose intravenous methylprednisolone in the treatment of severe acute respiratory syndrome. , 2004, Canadian Respiratory Journal.

[17]  M. Chan-yeung,et al.  High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. , 2003, American journal of respiratory and critical care medicine.

[18]  O. Tsang,et al.  Coronavirus-positive Nasopharyngeal Aspirate as Predictor for Severe Acute Respiratory Syndrome Mortality , 2003, Emerging infectious diseases.

[19]  J. Peiris,et al.  Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003 , 2003, The Lancet.

[20]  中华医学会,et al.  传染性非典型肺炎（SARS）诊疗方案 , 2003 .

[21]  P. Hawkey,et al.  Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. , 2003, Journal of medical microbiology.

[22]  P. Dong,et al.  [Use of glucocorticoid in treatment of severe acute respiratory syndrome cases]. , 2003, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[23]  R. Jiang,et al.  [Glucocorticoid in the treatment of severe acute respiratory syndrome patients: a preliminary report]. , 2003, Zhonghua nei ke za zhi.

[24]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[25]  Peter Cameron,et al.  A major outbreak of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[26]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[27]  K. Yuen,et al.  Development of a standard treatment protocol for severe acute respiratory syndrome , 2003, The Lancet.

[28]  Liu Yimin.  The clinical characteristics of secondary infections of lower respiratory tract in severe acute respiratory syndrome , 2003 .

[29]  G. Chrousos,et al.  Prolonged methylprednisolone treatment suppresses systemic inflammation in patients with unresolving acute respiratory distress syndrome: evidence for inadequate endogenous glucocorticoid secretion and inflammation-induced immune cell resistance to glucocorticoids. , 2002, American journal of respiratory and critical care medicine.

[30]  J. Davis,et al.  Nosocomial infections and nosocomial pneumonia. , 1996, American journal of surgery.

[31]  F. Stentz,et al.  Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS. Plasma IL-1 beta and IL-6 levels are consistent and efficient predictors of outcome over time. , 1995, Chest.

[32]  J. Murray,et al.  Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. , 1988, The American review of respiratory disease.

[33]  C. Sprung,et al.  High-dose corticosteroids in patients with the adult respiratory distress syndrome. , 1987, The New England journal of medicine.

[34]  J. Modig,et al.  High-dose methylprednisolone in a porcine model of ARDS induced by endotoxemia. , 1985, Acta chirurgica Scandinavica. Supplementum.